Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors

HIV Medicine

Volumn 10, Issue 6, 2009, Pages 351-355

  Benn, Paul ^a   Sauret Jackson, V ^b   Cartledge, J ^a   Ruff, C ^c   Sabin, C A ^d   Moyle, G ^e   Linney, A ^b   Reilly, G ^f   Edwards, S G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Cavendish Imaging and Cavendish Implants   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f Gilead Sciences   (United Kingdom)

Author keywords

3D surface laser scans; Abacavir; Facial lipoatrophy; HIV; Lipodystrophy; Stavudine; Tenofovir DF; Zidovudine

Indexed keywords

ABACAVIR; ANABOLIC AGENT; CORTICOSTEROID; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FACIAL LIPOATROPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MALE; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; ADENINE; ADULT; AGED; BODY COMPOSITION; CHEEK; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 67449163747     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00694.x     Document Type: Article

References (23)

1. Palella Jr FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Lumpkin MM. Reports of Diabetes and Hyperglycaemia in Patients Receiving Protease Inhibitors for the Treatment of Human Immunodeficiency Virus. Washington, DC: FDA Public Health Advisory, 1997.
3. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
4. Saint-Marc T, Poizot-Martin I, Partisani M et al. A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 1999 January-February [Abstract 653].
5. Ammassari A, Murri R, Pezzotti P et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445-449.
6. Duran S, Saves M, Spire B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001; 15: 2441-2444.
7. Blanch J, Rousaud A, Martinez E et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004; 38: 1464-1470.
8. Carey DL, Baker D, Rogers GD et al. A randomized, multicenter, open-label study of poly-l-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr 2007; 46: 581-589.
9. Moyle GJ, Lysakova L, Brown S et al. A randomized open-label study of immediate vs. delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5: 82-87.
10. Stewart DB, Morganroth GS, Mooney MA et al. Management of visible granulomas following periorbital injection of poly-l-lactic acid. Opthal Plast Reconstr Surg 2007; 23: 298-301.
11. Dijkema SJ, Van Der Lei B, Kibbelaar RE. New-Fill Injections may introduce late-onset foreign body granulomatous reaction. Plas Reconstr Surg 2005; 115: 76e-78e.
12. Mallal SA, John M, Moore CB et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-1316.
13. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. JAMA 2002; 288: 207-215.
14. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 2004; 18: 1029-1036.
15. Carr A, Law M, HIV Lipodystrophy Case Definition Study Group. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003; 33: 571-576.
16. Carey D, Wand H, Martin A et al. Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial. AIDS 2005; 19: 1325-1327.
17. Paton NI, Yang Y, Tha NO et al. Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging. HIV Clin Trials 2007; 8: 227-234.
18. Carey DL, Baker D, Rogers GD et al. A randomized, multicenter, open-label study of poly-l-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr 2007; 46: 581-589.
19. Benn P, Ruff C, Cartledge J et al. Overcoming subjectivity in assessing facial lipoatrophy: Is there a role for three-dimensional laser scans? HIV Med 2003; 4: 325-331.
20. Yang Y, Paton NI Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: Evaluation of accuracy and reproducibility. HIV Med 2005; 6: 321-325.
21. Yang Y, Sitoh YY, Oo Tha N et al. Facial fat volume in HIV-infected patients with lipoatrophy. Antivir Ther 2005; 10: 575-581.
22. Paton NI, Yang Y, Sitoh YY et al. Validation of three-dimensional laser scanning for the assessment of facial fat changes. HIV Med 2007; 8: 498-503.
23. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-2050.